A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China (Apr, 10.1007/s40261-023-01255-w, 2023)

作者:Jiang, Yanqing; Liu, Ruizhe; Xuan, Jianwei; Lin, Sisi; Zheng, Qiang; Zhang, Qun*; Pang, Jianxin*
来源:Clinical Drug Investigation, 2023, 43(5): 381-381.
DOI:10.1007/s40261-023-01269-4
  • 单位
    南方医科大学; 中山大学

全文